Calcium channel blockers in emergency medicine.
Diltiazem, nifedipine, and verapamil inhibit calcium entry into cells via different mechanisms with different pharmacologies. They display different relative effects on different cardiovascular functions, a complex interplay of direct actions and adrenergic reflexes. Peripheral arterial vasorelaxation causes adrenergic reflex activity which opposes their direct negative chronotropic, dromotropic, inotropic, and hypotensive actions. Verapamil's most potent activity is electrophysiologic, and nifedipine's effects are hemodynamic; diltiazem acts like a less-potent combination of verapamil and nifedipine. All three drugs are efficacious in angina. These three drugs may not be interchangeable in all patients, but individualization of therapy is possible. Future indications for calcium channel blocker therapy may include hypertrophic cardiomyopathy, cerebral vasospasm, migraine headaches, pulmonary hypertension, asthma, esophageal spasm, intestinal ischemia, Raynaud's phenomenon, dysmenorrhea, and premature labor.
D000200:Action Potentials; D000818:Animals; D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D004110:Diltiazem / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004630:Emergencies; D006331:Heart Diseases / Q000188:drug therapy; D006801:Humans; D009543:Nifedipine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014700:Verapamil / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D001552:Benzazepines; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D002118:Calcium